Rohit Malde

A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study

OPTIMAL: A Multinational Phase III Study of Oral Paclitaxel (DHP107) versus Intravenous Weekly Paclitaxel in HER2-Negative Recurrent or Metastatic Breast Cancer DOI: 10.1016/j.annonc.2026.03.002

Clinical practice guidelines for the diagnosis and treatment of diffuse glioma-related epilepsy: 2025 update Recommendations

Clinical practice guidelines for the diagnosis and treatment of diffuse glioma-related epilepsy: 2025 update doi.org/10.1016/j.canl…

The CGCG response assessment criteria for spinal cord gliomas doi.org/10.1016/j.canl…

Long-term outcomes of prophylactic cranial irradiation in high-risk metastatic NSCLC: Final PRoT-BM analysis

First Level-1 evidence for romiplostim in chemotherapy-induced thrombocytopenia. The RECITE Phase III trial (NEJM 2026) shows dramatic improvement in chemotherapy delivery: 84% vs 36% completed treatment without platelet-related dose changes. #MVOnco #Oncology

Functional SRS Globus Pallidotomy

Giredestrant New Kid on the Block Mechanism of action Overview of Trial Dilemma in trials Persevera Fails in Advanced Mets setting Lidera Sails in Adjuvant Setting

MRI to guide clinical management of rectal cancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)—Part 3

MRI to guide clinical management of rectal cancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)—Part 2

MRI to guide clinical management of rectalcancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)— Part 1

Does overall treatment time impact toxicity and clinical outcomes after MRI-guided stereotactic body radiotherapy to the prostate? An evaluation of the MOMENTUM repository. doi.org/10.1016/j.clon…

Actinomycin-D Extravasation

Low Risk GTN : Score </=6 Biweekly Actinomycin D Protocol

Gestational Trophoblastic Disease ( Invasive Mole) FIGO scoring Low Risk Vs High Risk Mgt = Highly Cureable

IO + Chemotherapy Trials in 1st Line setting for Advanced Unresectable Gastric / GEJ Cancer Orient 16: SINTILIMAB KEYNOTE-859: Pembrolizumab RATIONALE-305: Tislelizumab CheckMate 649: Nivolumab

Bridging & Downstaging Therapy in Hepatocellular Carcinoma Before Liver Transplant doi.org/10.1080/204509…

Met Amplification : Opening a can of Worms Whats Inside this Pandoras Box ?

Notable Cancer Medicines Added to the WHO Essential List in Sep 25 Snapshot of whats on 24th WHO essential List (2025) Targeted Therapies Immunomodulators Hormones and Antihormones

“Genomic Therapy Matching in Rare and Refractory Cancers” doi:10.1001/jamaoncol.2026.0127 Matching therapies to genomic biomarkers was associated with improved survival only when supported by prospective clinical trial evidence